ArticleStructural heart : the journal of the Heart Team2025
Prospective Evaluation of Neurocognition in Patients Following Transcatheter Aortic Valve Replacement.
Article in Structural heart : the journal of the Heart Team, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Aortic Valve Implantation and Cognitive Function: Treating the Heart, Altering the Brain?Structural heart : the journal of the Heart Team · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data regarding change in neurocognitive function after transcatheter aortic valve replacement (TAVR) are conflicting. We sought to investigate the change in cognition up to 6 months post-TAVR in patients with mild cognitive impairment (MCI). Methods: This is a prospective, observational, nonrandomized, cohort study of patients with MCI who underwent TAVR between February 2022 and June 2023 in a multicenter health care system. The inclusion criteria were TAVR patients with MCI, defined as a score of ≤25/30 on the Mini Montreal Cognitive Assessment (Mini MoCA) exam. The Mini MoCA exam was evaluated pre-TAVR, 30 days post-TAVR, and 6 months post-TAVR. Results: Of 81 enrolled TAVR patients, 73 (90.1%) and 66 (81.5%) completed 30-day and 6-month post-TAVR MoCA exams, respectively. The median age was 81 (IQR: 75.0-86.0) years and 47.4% were male. At baseline, history of stroke, transient ischemic attack, and dementia were 17.3, 9.9%, and 9.9%, respectively. The Mini MoCA scores showed a small but significant increase from the preoperative assessment to the 30-day interval (21.0 [17.5-22.5] vs. 22.0 [18.5-24.5]; Conclusions: Among patients with baseline MCI undergoing TAVR, neurocognitive function as measured by the Mini MoCA exam significantly improved at 30 days and 6 months postprocedure. TAVR in the setting of MCI is a safe therapeutic option for patients with aortic valve disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.